John Bencich, OncoGenex Pharmaceuticals Inc.'s CFO & COO, recently acquired 19 shares of the company. The buys took place at prices ranging from $0.00 to $1.16 per share, on January 15, 2019. Bencich now owns 1,139 shares of the company. Bencich operates out of Seattle, WA. Some additional info was provided as follows:
Represents shares of common stock acquired upon settlement of the restricted stock units ("RSUs") listed in Table II.
Represents shares of common stock that have been withheld by the Issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of RSUs and does not represent a sale by the reporting person.
Each restricted stock unit ("RSU") represents a contingent right to receive one share of the issuer'
s common stock at settlement.
Pursuant to the terms of the RSU, 25% of the total shares underlying the RSU vest annually on the later of (i) each anniversary of January 1, 2015 and (ii) the first day thereafter during which the issuer's trading window is open.
The above information was disclosed in a filing to the SEC. To see the filing, click here.
To receive a free e-mail notification whenever OncoGenex Pharmaceuticals Inc. makes a similar move, sign up!
Other recent filings from the company include the following:
EVP of OncoGenex Pharmaceuticals Inc. just picked up 962 shares - Aug. 15, 2019
OncoGenex Pharmaceuticals Inc.'s CFO & COO just picked up 962 shares - Aug. 15, 2019
OncoGenex Pharmaceuticals Inc. Just Filed Its Quarterly Report: 1. NATURE OF BUSINES... - Aug. 8, 2019
OncoGenex Pharmaceuticals: Achieve Reports Financial Results For Second Quarter 2019 And Provides Cytisinicline Clinical Development Update - Aug. 8, 2019
OncoGenex Pharmaceuticals Inc. Just Received a Notice of Effectiveness - Aug. 7, 2019